{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:23:22Z","timestamp":1792041802704,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-024-04006-2","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T03:30:21Z","timestamp":1735875021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases"],"prefix":"10.1186","volume":"25","author":[{"given":"Nozomi","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamitsu","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Egashira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Izumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"4006_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"4006_CR2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: Enestnd 3-year follow-up. Leukemia. 2012;26:2197\u2013203.","journal-title":"Leukemia"},{"key":"4006_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 pace trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood"},{"key":"4006_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","volume":"40","author":"A Manouchehri","year":"2020","unstructured":"Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J. Tyrosine kinase inhibitors in leukemia and cardiovascular events: From mechanism to patient care. Arterioscler Thromb Vasc Biol. 2020;40:301\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"4006_CR5","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa043033","volume":"352","author":"MI Chimowitz","year":"2005","unstructured":"Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305\u201316.","journal-title":"N Engl J Med"},{"issue":"9","key":"4006_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2174\/1568009617666171002142659","volume":"18","author":"M Fulvio","year":"2018","unstructured":"Fulvio M, Matteo M, Massimo B. Ponatinib: a review of efficacy and safety. Curr Cancer Drug Targets. 2018;18(9):847\u201356.","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"4006_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00701-021-05043-3","volume":"164","author":"A Hirayama","year":"2022","unstructured":"Hirayama A, Sorimachi T, Yokota K, Shigematsu H, Srivatanakul K, Matsumae M, et al. New-generation tyrosine kinase inhibitor-associated asymptomatic cerebrovascular stenosis: two illustrative cases. Acta Neurochir. 2022;164(6):1623\u20136.","journal-title":"Acta Neurochir"},{"key":"4006_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.7887\/jcns.30.804","volume":"30","author":"S Fujiwara","year":"2021","unstructured":"Fujiwara S, Fukumoto S, Miyazaki Y, Aso K, Ichikawa H, Onoue S, et al. A case of multiple arterial stenoses due to long-term nilotinib exposure. Jpn J Neurosurg. 2021;30:804\u201310.","journal-title":"Jpn J Neurosurg"},{"issue":"4","key":"4006_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/jch.13843","volume":"22","author":"SO Amin","year":"2020","unstructured":"Amin SO, Ruzicka M, Burns KD, Bence-Bruckler IA, Ryan SE, Hadziomerovic A, et al. Renovascular hypertension from the BCL-ABL tyrosine kinase inhibitor ponatinib. J Clin Hypertens. 2020;22(4):678\u201382.","journal-title":"J Clin Hypertens"},{"key":"4006_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ajh.23442","volume":"88","author":"EA Coon","year":"2013","unstructured":"Coon EA, Zalewski NL, Hoffman EM, Tefferi A, Flemming KD. Nilotinib treatment associated cerebrovascular disease and stroke. Am J Hematol. 2013;88:534\u20135.","journal-title":"Am J Hematol"},{"key":"4006_CR11","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/ccr3.729","volume":"4","author":"R Alshiekh-Nasany","year":"2016","unstructured":"Alshiekh-Nasany R, Zidan A, Martinez C. Extensive intra-cranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor nilotinib. Clin Case Rep. 2016;4:1184\u20136.","journal-title":"Clin Case Rep"},{"key":"4006_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/1591019917710810","volume":"23","author":"T Ozaki","year":"2017","unstructured":"Ozaki T, Nakamura H, Izutsu N, Masaie H, Ishikawa J, Kinoshita M. Intracranial stenting for nilotinib treatment associated cerebrovascular stenosis in chronic myeloid leukemia. Interv Neuroradiol. 2017;23:527\u201330.","journal-title":"Interv Neuroradiol"},{"key":"4006_CR13","doi-asserted-by":"publisher","first-page":"bcr2018013777","DOI":"10.1136\/bcr-2018-013777","volume":"2018","author":"CJ Chen","year":"2018","unstructured":"Chen CJ, Sorace BJ, Shakeri A, Park MS, Southerland AM, Worrall BB, et al. Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement. BMJ Case Rep. 2018;2018:bcr2018013777.","journal-title":"BMJ Case Rep"},{"key":"4006_CR14","first-page":"239","volume":"10","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Yamamoto J, Kakeda S, Takamatsu S, Miyaoka R, Kitagawa T, et al. Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib-associated cerebrovascular disease: a case report. Mol Clin Oncol. 2019;10:239\u201343.","journal-title":"Mol Clin Oncol"},{"key":"4006_CR15","first-page":"418","volume":"59","author":"A Nakaya","year":"2019","unstructured":"Nakaya A, Ebitani M, Monzen T, Nagno T, Saito F, Yaoita Y. A case of recurrent cerebral infarction during treatment with oral tyrosine kinase inhibitors for chronic myelogenous leukemia. Clin Neurol. 2019;59:418\u201324.","journal-title":"Clin Neurol"},{"key":"4006_CR16","doi-asserted-by":"publisher","first-page":"116577","DOI":"10.1016\/j.jns.2019.116577","volume":"408","author":"M Uemura","year":"2020","unstructured":"Uemura M, Kanazawa M, Yamagishi T, Nagai T, Takahashi M, Koide S, et al. Role of RNF213 p.4810K variant in the development of intracranial arterial disease in patients treated with nilotinib. J Neurol Sci. 2020;408:116577.","journal-title":"J Neurol Sci"},{"key":"4006_CR17","doi-asserted-by":"publisher","first-page":"105085","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105085","volume":"29","author":"E Spina","year":"2020","unstructured":"Spina E, Renna R, Lanterna LA, Colleoni ML, Andreone V. Progressive thrombosis of cervical and intracranial arteries related to ponatinib treatment for chronic myeloid leukemia. J Stroke Cerebrovasc Dis. 2020;29:105085.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"4006_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2176\/jns-nmc.2022-0298","volume":"10","author":"Y Rai","year":"2023","unstructured":"Rai Y, Hara T. Tyrosine kinase inhibitor-associated cerebral arterial occlusive disease treated with high-flow bypass surgery: a case report. NMC Case Rep. 2023;10:61\u20136.","journal-title":"NMC Case Rep"},{"key":"4006_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","volume":"59","author":"P Valent","year":"2017","unstructured":"Valent P, Hadzijusufovic E, Hoermann G, Fureder W, Schernthaner GH, Sperr WR, et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017;59:47\u201354.","journal-title":"Leuk Res"},{"key":"4006_CR20","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4006_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/ATVBAHA.120.314694","volume":"41","author":"MD Wu","year":"2021","unstructured":"Wu MD, Moslehi JJ, Lindner JR. Arterial thrombotic complications of tyrosine kinase inhibitors. Arterioscler Thromb Vasc Biol. 2021;41(1):3\u201310.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"20","key":"4006_CR22","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1042\/CS20160246","volume":"130","author":"S Gopal","year":"2016","unstructured":"Gopal S, Miller KB, Jaffe IZ. Molecular mechanisms for vascular complications of targeted cancer therapies. Clin Sci. 2016;130(20):1763\u201379.","journal-title":"Clin Sci"},{"key":"4006_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.leukres.2017.05.005","volume":"58","author":"M Sukegawa","year":"2017","unstructured":"Sukegawa M, Wang X, Nishioka C, Pan B, Xu K, Ohkawara H, et al. The bcr\/abl tyrosine kinase inhibitor, nilotinib, stimulates expression of il-1beta in vascular endothelium in association with downregulation of mir-3p. Leuk Res. 2017;58:83\u201390.","journal-title":"Leuk Res"},{"issue":"11","key":"4006_CR24","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","volume":"31","author":"E Hadzijusufovic","year":"2017","unstructured":"Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, et al. Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site. Leukemia. 2017;31(11):2388\u201397.","journal-title":"Leukemia"},{"key":"4006_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","volume":"5","author":"MG Pouwer","year":"2018","unstructured":"Pouwer MG, Pieterman EJ, Verschuren L, Caspers MPM, Kluft C, Garcia RA, et al. The bcr-abl1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front Cardiovasc Med. 2018;5:55.","journal-title":"Front Cardiovasc Med"},{"key":"4006_CR26","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","volume":"133","author":"Y Latifi","year":"2019","unstructured":"Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the bcr-abl1 tyrosine kinase inhibitor ponatinib. Blood. 2019;133:1597\u2013606.","journal-title":"Blood"},{"key":"4006_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/ejh.12367","volume":"94","author":"T Mirault","year":"2015","unstructured":"Mirault T, Rea D, Azarine A, Messas E. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome. Eur J Haematol. 2015;94:363\u20137.","journal-title":"Eur J Haematol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-04006-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-04006-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-04006-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T04:03:03Z","timestamp":1735876983000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-04006-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4006"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-04006-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"4 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients provided informed consent for all procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}